Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.

Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J.

Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30616-3. doi: 10.1016/S1470-2045(19)30616-3. [Epub ahead of print]

PMID:
31575503
2.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.

Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Gomez MD, Lowczak A, Aljumaily R, Lima CMR, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH; G1T28-02 Study Group.

Ann Oncol. 2019 Aug 27. pii: mdz278. doi: 10.1093/annonc/mdz278. [Epub ahead of print]

PMID:
31504118
3.

Intervention development and treatment success in UK health technology assessment funded trials of physical rehabilitation: a mixed methods analysis.

Goodwin VA, Hill JJ, Fullam JA, Finning K, Pentecost C, Richards DA.

BMJ Open. 2019 Aug 28;9(8):e026289. doi: 10.1136/bmjopen-2018-026289.

4.

Provenance of uranium particulate contained within Fukushima Daiichi Nuclear Power Plant Unit 1 ejecta material.

Martin PG, Louvel M, Cipiccia S, Jones CP, Batey DJ, Hallam KR, Yang IAX, Satou Y, Rau C, Mosselmans JFW, Richards DA, Scott TB.

Nat Commun. 2019 Jun 26;10(1):2801. doi: 10.1038/s41467-019-10937-z.

5.

Oriented attachment of VNAR proteins, via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance.

Nogueira JCF, Greene MK, Richards DA, Furby AO, Steven J, Porter A, Barelle C, Scott CJ, Chudasama V.

Chem Commun (Camb). 2019 Jun 27;55(53):7671-7674. doi: 10.1039/c9cc02655j.

PMID:
31204425
6.

Impact of telephone delivered case-management on the effectiveness of collaborative care for depression and anti-depressant use: A systematic review and meta-regression.

Hudson JL, Bower P, Kontopantelis E, Bee P, Archer J, Clarke R, Moriarty AS, Richards DA, Gilbody S, Lovell K, Dickens C, Gask L, Waheed W, Coventry PA.

PLoS One. 2019 Jun 14;14(6):e0217948. doi: 10.1371/journal.pone.0217948. eCollection 2019.

7.

Morita Therapy for depression (Morita Trial): an embedded qualitative study of acceptability.

Sugg HVR, Frost J, Richards DA.

BMJ Open. 2019 May 29;9(5):e023873. doi: 10.1136/bmjopen-2018-023873.

8.

Distinct Phenotypes Induced by Three Degrees of Transverse Aortic Constriction in Mice.

Richards DA, Aronovitz MJ, Calamaras TD, Tam K, Martin GL, Liu P, Bowditch HK, Zhang P, Huggins GS, Blanton RM.

Sci Rep. 2019 Apr 10;9(1):5844. doi: 10.1038/s41598-019-42209-7.

9.

'Shitty nursing' - The new normal?

Richards DA, Borglin G.

Int J Nurs Stud. 2019 Mar;91:148-152. doi: 10.1016/j.ijnurstu.2018.12.018. Epub 2018 Dec 31.

PMID:
30831477
10.

Use of patient-reported outcome measures (PROMs) in clinical diabetes consultations: study protocol for the DiaPROM randomised controlled trial pilot study.

Haugstvedt A, Hernar I, Strandberg RB, Richards DA, Nilsen RM, Tell GS, Graue M.

BMJ Open. 2019 Jan 17;9(1):e024008. doi: 10.1136/bmjopen-2018-024008.

11.

Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery.

Richards DA.

Drug Discov Today Technol. 2018 Dec;30:35-46. doi: 10.1016/j.ddtec.2018.10.005. Epub 2018 Nov 8. Review.

12.

Spatial pattern of plutonium and radiocaesium contamination released during the Fukushima Daiichi nuclear power plant disaster.

Dunne JA, Martin PG, Yamashiki Y, Ang IXY, Scott TB, Richards DA.

Sci Rep. 2018 Nov 14;8(1):16799. doi: 10.1038/s41598-018-34302-0.

13.

Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.

Calamaras TD, Baumgartner RA, Aronovitz MJ, McLaughlin AL, Tam K, Richards DA, Cooper CW, Li N, Baur WE, Qiao X, Wang GR, Davis RJ, Kapur NK, Karas RH, Blanton RM.

Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H145-H159. doi: 10.1152/ajpheart.00029.2018. Epub 2018 Oct 26.

PMID:
30362822
14.

The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.

Burgess SN, French JK, Nguyen TL, Leung M, Richards DAB, Thomas L, Mussap C, Lo S, Juergens CP.

Am Heart J. 2018 Nov;205:31-41. doi: 10.1016/j.ahj.2018.07.017. Epub 2018 Jul 29.

PMID:
30153623
15.

The Second Triennial Systematic Literature Review of European Nursing Research: Impact on Patient Outcomes and Implications for Evidence-Based Practice.

Richards DA, Hanssen TA, Borglin G.

Worldviews Evid Based Nurs. 2018 Oct;15(5):333-343. doi: 10.1111/wvn.12320. Epub 2018 Aug 20.

PMID:
30129094
16.

Morita Therapy for depression (Morita Trial): a pilot randomised controlled trial.

Sugg HVR, Richards DA, Frost J.

BMJ Open. 2018 Aug 10;8(8):e021605. doi: 10.1136/bmjopen-2018-021605.

17.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J.

Cancer Chemother Pharmacol. 2018 Aug;82(2):285-298. doi: 10.1007/s00280-018-3610-z. Epub 2018 Jun 7.

18.

Enhanced psychological care in cardiac rehabilitation services for patients with new-onset depression: the CADENCE feasibility study and pilot RCT.

Richards SH, Campbell JL, Dickens C, Anderson R, Gandhi M, Gibson A, Kessler D, Knight L, Kuyken W, Richards DA, Taylor RS, Turner K, Ukoumunne OC, Davey A, Warren FC, Winder RE, Wright CA.

Health Technol Assess. 2018 May;22(30):1-220. doi: 10.3310/hta22300.

19.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.

20.

Forming next-generation antibody-nanoparticle conjugates through the oriented installation of non-engineered antibody fragments.

Greene MK, Richards DA, Nogueira JCF, Campbell K, Smyth P, Fernández M, Scott CJ, Chudasama V.

Chem Sci. 2017 Aug 14;9(1):79-87. doi: 10.1039/c7sc02747h. eCollection 2018 Jan 7.

21.

Assessing the effectiveness of Enhanced Psychological Care for patients with depressive symptoms attending cardiac rehabilitation compared with treatment as usual (CADENCE): a pilot cluster randomised controlled trial.

Richards SH, Dickens C, Anderson R, Richards DA, Taylor RS, Ukoumunne OC, Turner KM, Gandhi M, Kuyken W, Gibson A, Davey A, Warren F, Winder R, Campbell J.

Trials. 2018 Apr 2;19(1):211. doi: 10.1186/s13063-018-2576-9.

22.

Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones.

Bahou C, Richards DA, Maruani A, Love EA, Javaid F, Caddick S, Baker JR, Chudasama V.

Org Biomol Chem. 2018 Feb 21;16(8):1359-1366. doi: 10.1039/c7ob03138f.

23.

Increasing value and reducing waste by optimizing the development of complex interventions: Enriching the development phase of the Medical Research Council (MRC) Framework.

Bleijenberg N, de Man-van Ginkel JM, Trappenburg JCA, Ettema RGA, Sino CG, Heim N, Hafsteindóttir TB, Richards DA, Schuurmans MJ.

Int J Nurs Stud. 2018 Mar;79:86-93. doi: 10.1016/j.ijnurstu.2017.12.001. Epub 2017 Dec 5.

24.

Platinum Nanocatalyst Amplification: Redefining the Gold Standard for Lateral Flow Immunoassays with Ultrabroad Dynamic Range.

Loynachan CN, Thomas MR, Gray ER, Richards DA, Kim J, Miller BS, Brookes JC, Agarwal S, Chudasama V, McKendry RA, Stevens MM.

ACS Nano. 2018 Jan 23;12(1):279-288. doi: 10.1021/acsnano.7b06229. Epub 2017 Dec 22.

25.
26.

CollAborative care for Screen-Positive EldeRs with major depression (CASPER plus): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness.

Bosanquet K, Adamson J, Atherton K, Bailey D, Baxter C, Beresford-Dent J, Birtwistle J, Chew-Graham C, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hamilton J, Hargate R, Hewitt C, Holmes J, Keding A, Lewis H, McMillan D, Meer S, Mitchell N, Nutbrown S, Overend K, Parrott S, Pervin J, Richards DA, Spilsbury K, Torgerson D, Traviss-Turner G, Trépel D, Woodhouse R, Gilbody S.

Health Technol Assess. 2017 Nov;21(67):1-252. doi: 10.3310/hta21670.

27.

Stakeholders perspectives on the key components of community-based interventions coordinating care in dementia: a qualitative systematic review.

Backhouse A, Richards DA, McCabe R, Watkins R, Dickens C.

BMC Health Serv Res. 2017 Nov 22;17(1):767. doi: 10.1186/s12913-017-2725-y. Review.

28.

Fundamental nursing care: A systematic review of the evidence on the effect of nursing care interventions for nutrition, elimination, mobility and hygiene.

Richards DA, Hilli A, Pentecost C, Goodwin VA, Frost J.

J Clin Nurs. 2018 Jun;27(11-12):2179-2188. doi: 10.1111/jocn.14150. Epub 2018 Jan 10. Review.

29.

The effectiveness of community-based coordinating interventions in dementia care: a meta-analysis and subgroup analysis of intervention components.

Backhouse A, Ukoumunne OC, Richards DA, McCabe R, Watkins R, Dickens C.

BMC Health Serv Res. 2017 Nov 13;17(1):717. doi: 10.1186/s12913-017-2677-2. Review.

30.

Echocardiographic evaluation of diastolic function in mouse models of heart disease.

Schnelle M, Catibog N, Zhang M, Nabeebaccus AA, Anderson G, Richards DA, Sawyer G, Zhang X, Toischer K, Hasenfuss G, Monaghan MJ, Shah AM.

J Mol Cell Cardiol. 2018 Jan;114:20-28. doi: 10.1016/j.yjmcc.2017.10.006. Epub 2017 Oct 19.

31.

Optimising the acceptability and feasibility of novel complex interventions: an iterative, person-based approach to developing the UK Morita therapy outpatient protocol.

Sugg HVR, Richards DA, Frost J.

Pilot Feasibility Stud. 2017 Oct 3;3:37. doi: 10.1186/s40814-017-0181-4. eCollection 2017.

32.

Patients' and nurses' views on providing psychological support within cardiac rehabilitation programmes: a qualitative study.

Turner KM, Winder R, Campbell JL, Richards DA, Gandhi M, Dickens CM, Richards S.

BMJ Open. 2017 Sep 1;7(9):e017510. doi: 10.1136/bmjopen-2017-017510.

33.

Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression.

Richards DA, Rhodes S, Ekers D, McMillan D, Taylor RS, Byford S, Barrett B, Finning K, Ganguli P, Warren F, Farrand P, Gilbody S, Kuyken W, O'Mahen H, Watkins E, Wright K, Reed N, Fletcher E, Hollon SD, Moore L, Backhouse A, Farrow C, Garry J, Kemp D, Plummer F, Warner F, Woodhouse R.

Health Technol Assess. 2017 Aug;21(46):1-366. doi: 10.3310/hta21460.

34.

The actin binding protein scinderin acts in PC12 cells to tether dense-core vesicles prior to secretion.

Wang J, Richards DA.

Mol Cell Neurosci. 2017 Dec;85:12-18. doi: 10.1016/j.mcn.2017.08.003. Epub 2017 Aug 18.

35.
36.

Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG Iα (Protein Kinase G Iα).

Burgoyne JR, Prysyazhna O, Richards DA, Eaton P.

Hypertension. 2017 Sep;70(3):577-586. doi: 10.1161/HYPERTENSIONAHA.117.09670. Epub 2017 Jul 17.

37.

Shape of change in internet based behavioral activation treatment for depression.

O'Mahen HA, Wilkinson E, Bagnall K, Richards DA, Swales A.

Behav Res Ther. 2017 Aug;95:107-116. doi: 10.1016/j.brat.2017.05.011. Epub 2017 May 17.

PMID:
28618298
38.

Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering.

Lee MTW, Maruani A, Richards DA, Baker JR, Caddick S, Chudasama V.

Chem Sci. 2017 Mar 1;8(3):2056-2060. doi: 10.1039/c6sc03655d. Epub 2016 Nov 28.

39.

Antibody fragments as nanoparticle targeting ligands: a step in the right direction.

Richards DA, Maruani A, Chudasama V.

Chem Sci. 2017 Jan 1;8(1):63-77. doi: 10.1039/c6sc02403c. Epub 2016 Sep 16.

40.

A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure.

Aubdool AA, Thakore P, Argunhan F, Smillie SJ, Schnelle M, Srivastava S, Alawi KM, Wilde E, Mitchell J, Farrell-Dillon K, Richards DA, Maltese G, Siow RC, Nandi M, Clark JE, Shah AM, Sams A, Brain SD.

Circulation. 2017 Jul 25;136(4):367-383. doi: 10.1161/CIRCULATIONAHA.117.028388. Epub 2017 Apr 26.

41.

Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a qualitative process evaluation.

Finning K, Richards DA, Moore L, Ekers D, McMillan D, Farrand PA, O'Mahen HA, Watkins ER, Wright KA, Fletcher E, Rhodes S, Woodhouse R, Wray F.

BMJ Open. 2017 Apr 13;7(4):e014161. doi: 10.1136/bmjopen-2016-014161.

42.

Distinct Regulatory Effects of Myeloid Cell and Endothelial Cell NAPDH Oxidase 2 on Blood Pressure.

Sag CM, Schnelle M, Zhang J, Murdoch CE, Kossmann S, Protti A, Santos CXC, Sawyer G, Zhang X, Mongue-Din H, Richards DA, Brewer AC, Prysyazhna O, Maier LS, Wenzel P, Eaton PJ, Shah AM.

Circulation. 2017 May 30;135(22):2163-2177. doi: 10.1161/CIRCULATIONAHA.116.023877. Epub 2017 Mar 15.

43.

Development and refinement of a complex intervention within cardiac rehabilitation services: experiences from the CADENCE feasibility study.

Winder R, Richards SH, Campbell JL, Richards DA, Dickens C, Gandhi M, Wright C, Turner K.

Pilot Feasibility Stud. 2017 Feb 13;3:9. doi: 10.1186/s40814-017-0123-1. eCollection 2017.

44.

Telephone-supported computerised cognitive-behavioural therapy: REEACT-2 large-scale pragmatic randomised controlled trial.

Gilbody S, Brabyn S, Lovell K, Kessler D, Devlin T, Smith L, Araya R, Barkham M, Bower P, Cooper C, Knowles S, Littlewood E, Richards DA, Tallon D, White D, Worthy G; REEACT collaborative.

Br J Psychiatry. 2017 May;210(5):362-367. doi: 10.1192/bjp.bp.116.192435. Epub 2017 Mar 2.

45.

Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial.

Gilbody S, Lewis H, Adamson J, Atherton K, Bailey D, Birtwistle J, Bosanquet K, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hamilton J, Hargate R, Hewitt C, Holmes J, Keding A, Lilley-Kelly A, Meer S, Mitchell N, Overend K, Pasterfield M, Pervin J, Richards DA, Spilsbury K, Traviss-Turner G, Trépel D, Woodhouse R, Ziegler F, McMillan D.

JAMA. 2017 Feb 21;317(7):728-737. doi: 10.1001/jama.2017.0130.

46.

Behavioural activation training for depression - Authors' reply.

Richards DA, Finning K, Taylor RS.

Lancet. 2017 Jan 28;389(10067):367-368. doi: 10.1016/S0140-6736(17)30160-5. No abstract available.

PMID:
28137694
47.

Mass Spectrometry Based Metabolomics Comparison of Liver Grafts from Donors after Circulatory Death (DCD) and Donors after Brain Death (DBD) Used in Human Orthotopic Liver Transplantation.

Hrydziuszko O, Perera MT, Laing R, Kirwan J, Silva MA, Richards DA, Murphy N, Mirza DF, Viant MR.

PLoS One. 2016 Nov 11;11(11):e0165884. doi: 10.1371/journal.pone.0165884. eCollection 2016.

48.

Association Between Chronic Physical Conditions and the Effectiveness of Collaborative Care for Depression: An Individual Participant Data Meta-analysis.

Panagioti M, Bower P, Kontopantelis E, Lovell K, Gilbody S, Waheed W, Dickens C, Archer J, Simon G, Ell K, Huffman JC, Richards DA, van der Feltz-Cornelis C, Adler DA, Bruce M, Buszewicz M, Cole MG, Davidson KW, de Jonge P, Gensichen J, Huijbregts K, Menchetti M, Patel V, Rollman B, Shaffer J, Zijlstra-Vlasveld MC, Coventry PA.

JAMA Psychiatry. 2016 Sep 1;73(9):978-89. doi: 10.1001/jamapsychiatry.2016.1794.

49.

Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial.

Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, Barrett B, Farrand PA, Gilbody S, Kuyken W, O'Mahen H, Watkins ER, Wright KA, Hollon SD, Reed N, Rhodes S, Fletcher E, Finning K.

Lancet. 2016 Aug 27;388(10047):871-80. doi: 10.1016/S0140-6736(16)31140-0. Epub 2016 Jul 23.

50.

High-resolution radiation mapping to investigate FDNPP derived contaminant migration.

Martin PG, Payton OD, Yamashiki Y, Richards DA, Scott TB.

J Environ Radioact. 2016 Nov;164:26-35. doi: 10.1016/j.jenvrad.2016.06.025. Epub 2016 Jul 7.

Supplemental Content

Loading ...
Support Center